Physician profile
Rina Gupta
NPI 1669968657
$1,479.77
in general payments reported to CMS, 2019-2025
16 companies · $1,201 in 2025
The $1,201 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $279 · 2025: $1,201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,480.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,479.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $511.50 | 2024-2025 | Tavneos, Otezla, Enbrel |
| Ucb, INC. | $223.32 | 2024-2025 | Bimzelx |
| Abbvie INC. | $217.22 | 2024-2025 | |
| Organon LLC | $103.81 | 2024-2025 | Renflexis, Hadlima |
| Pfizer INC. | $64.37 | 2025 | |
| Glaxosmithkline, LLC. | $58.45 | 2024-2025 | Benlysta |
| Aurinia Pharma U.S., INC. | $51.16 | 2025 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $48.78 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $43.10 | 2024-2025 | Orencia |
| Genzyme Corporation | $31.01 | 2025 | |
| Mallinckrodt Hospital Products INC. | $30.63 | 2024 | Acthar |
| Fresenius Kabi USA, LLC | $27.29 | 2025 | Tyenne |
| Lilly USA, LLC | $19.45 | 2024 | Taltz |
| Scilex Pharmaceuticals INC. | $19.30 | 2025 | |
| Janssen Biotech, INC. | $15.30 | 2025 | Tremfya |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $15.08 | 2025 | Saphnelo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rina Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.